Related Experiment Videos
Deregulation of the IL-1β axis in chronic recurrent multifocal osteomyelitis
Roberta Scianaro1, Antonella Insalaco1, Luisa Bracci Laudiero1
1Rheumatology Unit, Bambino Gesù Children's Hospital, Rome, Italy.
Background:
This study aims to investigate the inflammasome response in peripheral blood mononuclear cells (PBMCs) and the expression of inflammasome components in bone biopsies from patients with chronic recurrent multifocal osteomyelitis (CRMO).
Methods:
The expression of inflammasome components mRNAs was evaluated in PBMCs isolated from 15 CRMO patients and 13 healthy controls by quantitative real-time PCR. The Interleukin (IL)-1β released in the medium of PBMC cultures after treatment with lipopolysaccharides (LPS) alone or LPS and ATP was measured by ELISA. Immunohistochemical staining for Apoptosis-associated Speck-like protein (ASC), caspase-1 (CASP-1), Nod-like receptor protein-3 (NLRP3) and IL-1β expression was performed in bone biopsies from CRMO patients.
Results:
mRNA levels of ASC, CASP-1 and IL-1β were significantly higher in freshly isolated PBMCs from CRMO patients in active disease than in healthy controls. CASP-1 and IL-1β transcript levels were significantly higher also in PBMCs from CRMO patients in remission compared to healthy controls. PBMCs from CRMO patients in active disease stimulated in vitro with LPS showed a significant increase in IL-1β release compared to healthy control cells. Immunohistochemistry staining of bone tissue revealed the expression of inflammasome components in CRMO osteoclasts.
Conclusions:
Our data suggest that an abnormal regulation of IL-1β axis may be involved in CRMO pathogenesis.
Insights
Chronic recurrent multifocal osteomyelitis (CRMO) involves inflammasome activation. Elevated Interleukin-1 beta (IL-1β) in peripheral blood mononuclear cells (PBMCs) and bone suggests its role in CRMO.
Area of Science:
- Immunology
- Rheumatology
- Molecular Biology
Background:
- Chronic recurrent multifocal osteomyelitis (CRMO) is a rare autoinflammatory bone disease.
- The role of inflammasomes in CRMO pathogenesis remains incompletely understood.
Purpose of the Study:
- To investigate inflammasome component expression in peripheral blood mononuclear cells (PBMCs) and bone biopsies of CRMO patients.
- To analyze the Interleukin-1 beta (IL-1β) pathway in CRMO.
Main Methods:
- Quantitative real-time PCR for inflammasome mRNA in PBMCs from 15 CRMO patients and 13 controls.
- ELISA for IL-1β release from stimulated PBMCs.
- Immunohistochemistry for inflammasome components (ASC, CASP-1, NLRP3, IL-1β) in CRMO bone biopsies.
Main Results:
- Significantly higher mRNA levels of ASC, CASP-1, and IL-1β in PBMCs from CRMO patients (active and remission) compared to controls.
- Increased IL-1β release from LPS-stimulated PBMCs of CRMO patients.
- Inflammasome components detected in CRMO osteoclasts within bone tissue.
Conclusions:
- Abnormal regulation of the IL-1β axis is implicated in CRMO pathogenesis.
- Inflammasome activation in PBMCs and bone may contribute to CRMO.
Related Concept Videos
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Inflammatory Response
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
The JAK-STAT Signaling Pathway
Chronic Inflammation: Introduction
Osteoclasts in Bone Remodeling